Even though screening the general population does not impact mortality or CVD incidence, it did have benefits for those diagnosed with diabetes.

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) list a hierarchy of usage for antihyperglycemic medications after metformin. Which one of the following lists shows the correct hierarchy, beginning with the most preferred? A. A Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones (TZDs), basal insulins B. SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 RAs, TZDs, basal insulins C. TZDs, GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors, basal insulins D. GLP-1 RAs, SGLT-2 inhibitors, basal insulins, DPP-4 inhibitors, TZDs Follow the link to see the right answer.

Do you feel that continuous blood glucose monitoring (CGM) will eventually replace blood glucose monitors? Follow the link to share your response.

Dr. Todd Hobbs is Vice President and Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system, and healthcare professionals. He provides overall medical guidance to Novo Nordisk’s diabetes and obesity-related projects. Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the medicine department for a large regional medical center in Kentucky. During this 10year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.

Dr. Todd Hobbs discusses diabetes and obesity related projects at Novo Nordisk, including the results of the DEVOTE trial: the cardiovascular outcomes trial for degludec, basal insulin.

n this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about data from various important trials as well as the importance of their unique product degludec.

In part 1 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about his work at Novo Nordisk not only as chief medical officer but also as a person with type 1.

In part 2 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about DEVOTE data and how degludec works.

In part 3 of this Exclusive Interview, Dr. Todd Hobbs explains the DUAL-7 data in a converstion with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 4 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the GLP-1 cardiovascular trials and the significance of the LEADER study.